Hormone Deficiency in Heart Failure With Preserved Ejection Fraction

Multiple Hormone Deficiency Syndrome in Heart Failure With Preserved Ejection Fraction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02976350

Acronym

MHDS in HFpEF

Enrollment

Registered

2016-11-29

Start date

2015-01-31

Completion date

2015-09-30

Last updated

2016-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Hormone Deficiencies

Keywords

Heart failure, Heart failure with preserved ejection fraction, GH deficiency, Testosterone deficiency, Low- T3 syndrome, Multiple Hormone Deficiencies

Brief summary

The objective of this study is to describe the prevalence of Multiple Hormone Deficiencies in Heart Failure with preserved Ejection Fraction.

Detailed description

Despite the effectiveness of the neurohormonal model to explain the progression of heart failure and the many insights that it provided for the development of new therapies, there is increasing clinical evidence that suggests that our current models fail to completely explain the disease progression. Thus, neurohormonal models may be necessary but not sufficient to explain all aspects of disease progression in the failing heart. There is evidence suggesting that in heart failure there is a metabolic imbalance characterized by the predominance of the catabolic status over the anabolic drive. Consistent data coming from several independent groups have documented the reduced activity of most anabolic axes in HF with reduced ejection fraction. To date, no study has addressed the prevalence the presence and the prevalence of the Multiple Hormone Deficiencies in Heart Failure with preserved Ejection Fraction.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male patients of affected by CHF, secondary to ischemic or idiopathic dilated cardiomyopathy * left ventricle ejection fraction \> 50% or more

Exclusion criteria

* severe liver disease * serum creatinine levels \>2.5 mg/dl * history of active cancer with life expectancy below 1 year acute coronary syndrome in the previous 6 months

Design outcomes

Primary

Measure	Time frame
Prevalence of Hormone deficiency	1 months

Countries

Italy

Outcome results